[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)
date : 11/5/2020
Tags: AMR
![[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)](https://hgpi.org/en/wp-content/uploads/sites/2/AMRalliance-logo-13.jpg)
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) held a Roundtable on Medical Fee System Measures to Discourage the Spread of AMR.
This meeting was held on the basis of AMR Alliance Japan’s overarching policy recommendations published in July 2019 which called for the promotion of measures through the medical fee system to incentivize behaviors that could help to discourage the spread of antimicrobial resistance (AMR).
AMR Alliance Japan members discussed recommendations toward the 2022 revision of the medical fee system. Based on the discussion, AMR Alliance Japan decided on the key items to be targeted in future proposals on the medical fee system revision.
In light of the situation with novel coronavirus, this meeting was carried out primarily online.
■Overview
Date and time: Wednesday, September 28, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
Roundtable Discussion
・Key items for AMR Alliance Japan’s Medical Fee System Revision Proposal
・Future Plans
■Roundtable Speakers (alphabetical order by last name):
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Masashi Kawata (Senior Manager, Public Affairs & Policy, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Masaaki Miyakawa (Executive Board Member, Japan Medical Association)
Choichiro Miyazaki (Vice Chairman, Japan Pharmaceutical Association)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Toshiyuki Sakaeda (President, The Japanese Society of Therapeutic Drug Monitoring / Professor, Department of Pharmacokinetics, Kyoto Pharmaceutical University)
Makoto Seno (Marketing Director, Nippon Becton Dickinson Company Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
■Moderator:
Yuki Awano (AMR Alliance Japan Secretariat / Associate, HGPI)
Top Research & Recommendations Posts
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-12-03
[Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
-
2023-12-04
[Registration Open] (Webinar) The 122nd HGPI Seminar: Keeping Pace with Growing Diversity of Health Information in Health Communication (December 19, 2023)
-
2023-12-05
[Policy Recommendations] Recommendation: Suggestions for Building a Resilient and Greener Health Care System Considering Sustainability and Environmental Concerns in the Revision of Medical, Nursing Care, and Disability Welfare Service Fees (December 6, 2023)
-
2023-12-05
[Registration Open] Online Global Expert Meeting: Considering Participation Among People Living with Dementia in the Formulation of National Dementia Strategies and in Policy Making Processes (January 22, 2024)